Company: DMAAR
Filing Date: 2025-11-18
Form Type: 10-Q
Source: 0001213900-25-112096
Chunk: 60

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-11-18
Form: 10-Q
Item: Part I, Item 8
Chunk 60
---
 on February 18, 2025 an amount of
$231,150,000 ($10.05 per Unit) from the net proceeds of the sale of the Units in the Initial Public Offering and the sale of the Private
Placement Units was placed in a trust account (“Trust Account”), located in the United States and invested only in U.S. government
treasury obligations with a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7
under the Investment Company Act which invest only in direct U.S. government treasury obligations and/or held as cash or cash items
(including in demand deposit accounts), as determined by the Company, until the earlier of: (i) the completion of a Business Combination;
(ii) the redemption of any Public Shares properly submitted in connection with a shareholder vote to amend the Company’s amended
and restated memorandum and articles of association (A) to modify the substance or timing of the Company’s obligation to allow
redemption in connection with its initial business combination or to redeem 100% of the Public Shares if the Company does not complete
its initial business combination within the Combination Period (as defined below) or (B) with respect to any other material provisions
relating to shareholders’ rights or pre-initial business combination activity; and (iii) the redemption of the Public Shares
if the Company has not completed an initial business combination within the Combination Period, subject to applicable law, as described
below.

Transaction
costs amounted to $8,898,201 consisting of $1,150,000 of cash underwriting fees, $6,900,000 of deferred underwriting fees, and $848,201
of other offering costs.

The
Company will provide the holders of the outstanding Public Shares (the “Public Shareholders”) with the opportunity to redeem
all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a shareholder
meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will
seek shareholder approval of a Business Combination or conduct a tender offer will be made by the Company. The Public Shareholders will
be entitled to redeem their Public Shares for a pro rata portion of the amount then in the Trust Account (initially $10.05 per Public
Share, plus any pro rata interest then in the Trust Account, net of taxes payable). There